drugset / Trial / NCT06642558
Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above
Phase 1/2
Active not recruiting
522 enrolled
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the safety and immunogenicity of two dose levels of the single dose Recombinant RSV vaccine(CHO cells), when administered intramuscularly (IM) in healthy adults aged 18 years and older.
Timeline
- Start
- 2024-11-13
- Primary completion
- 2025-06-30
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) | Vaccine | 0.25 ml | Intramuscular |
| Subject | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) | Vaccine | 0.5 ml | Intramuscular |